Intermediate-affinity CD19-directed CAR T cell product obecabtagene autoleucel demonstrates favourable safety and efficacy in R/R B-ALL.
作者信息
Faramand Rawan G, Locke Frederick L
机构信息
Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA.
出版信息
Nat Rev Clin Oncol. 2025 Mar;22(3):161-162. doi: 10.1038/s41571-025-00993-4.
PMID:39930262
Abstract
摘要
Zotero 插件